Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 251 (11), 1297-303

Hepatic Injury, Liver Monitoring and the Beta-Interferons for Multiple Sclerosis

Affiliations
Review

Hepatic Injury, Liver Monitoring and the Beta-Interferons for Multiple Sclerosis

Helen Tremlett et al. J Neurol.

Abstract

This review explores the salient issues surrounding liver injury and liver monitoring associated with beta-interferon (IFNB) treatment for multiple sclerosis (MS). Post-marketing studies have found a higher proportion of IFNB-treated MS patients with elevated aminotransferases than reported in the pivotal clinical trials. Although the risk of severe liver injury appears small, the true incidence is unknown. Post-marketing studies have shown that the greatest period of risk for the development of liver test abnormalities appears to be in the first year of IFNB treatment. The risk also increases with the more frequently administered, higher-dosage IFNBs. Males are more likely than females to develop elevated aminotransferases (> upper normal limit), although females appear at a greater risk of severe liver injury. Of the commonly used biochemical liver tests, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP) and bilirubin appear the most useful for routine monitoring of IFNB treatment. Whilst many other factors can affect liver test results, including obesity, alcohol, concomitant medications, co-morbidities and theoretically even MS itself, regular liver testing both prior and during IFNB therapy might help minimise Type A or dose/frequency dependent aminotransferase elevations. However, testing will probably not prevent the Type B idiosyncratic reactions which can result in severe hepatic injury; hence patients need to be aware, and to report hepatic side effects promptly.

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

References

    1. J Gastroenterol. 2002;37(8):617-25 - PubMed
    1. Am J Gastroenterol. 1996 Oct;91(10 ):2233-4 - PubMed
    1. Ann Neurol. 1996 Mar;39(3):285-94 - PubMed
    1. Semin Oncol. 1992 Oct;19(5):551-65 - PubMed
    1. J Clin Pharm Ther. 2001 Dec;26(6):437-44 - PubMed

Publication types

MeSH terms

Substances

Feedback